Method of surgical laser treatment of impaired patency of the horizontal and vertical lacrimal DEPARTMENT OF STAFF

摘要

a surgical laser u043bu0435u0447u0435u043du0438u00a0 violations launch of horizontal and vertical sections u0441u043bu0435u0437u043eu043eu0442u0432u043eu0434u00a0u0449u0435u0433u043e apparatus comprising a on it u0437u043du043eu043cu0443 u043au0430u043du0430u043bu044cu0446u0443 until it locks in the bone, fibre optics and laser perforations laser radiation bone u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 so that the tip growth with which it st. u0435u0442u043eu0432u043eu0434u043eu043c laser through u0441u043bu0435u0437u043du0443u044e pointthe lower or upper tires u043au0430u043du0430u043bu0435u0446 and cavity u0441u043bu0435u0437u043du043eu0433u043e bag u0432u0432u043eu0434u00a0u0442 until its contact to the u0441u043bu0435u0437u043du043eu0439 bones or u043bu043eu0431u043du043eu043cu0443 u043eu0442u0440u043eu0441u0442u043au0443 upper jaw, for nasal cavity u043fu043eu043bu043du00a0u044eu0442 u0433u0438u0434u0440u043eu0433u0435u043bu0435u043c, then using a pulse laser with the wavelength of u0438u0437u043bu0443u0447u0435u043du0438u00a0 1437 - 14 nm.a frequency of 10 to 30 hz and a 350 - 450 mj laser pulse with duration of 150 - 250 ms or pulse laser with the wavelength of the periodic u0438u0437u043bu0443u0447u0435u043du0438u00a0 810 - 2000 nm, often the 10 - 100 hz, and the power of the laser u0438u0437u043bu0443u0447u0435u043du0438u00a0 3 - 50 w or continuous laser with a wavelength of 810 u0438u0437u043bu0443u0447u0435u043du0438u00a0 - 2000 nm.a frequency of 10 to 100 hz and the power of the laser u0438u0437u043bu0443u0447u0435u043du0438u00a0 3 - 50 w to form a bone window first diameter 0.8 - 1.3 mm, u043fu0440u043eu0434u0432u0438u0433u0430u00a0 relapsing progressive movements of the laser light guide as it u0443u0433u043bu0443u0431u043bu0435u043du0438u00a0 in bone tissue u0441u043bu0435u0437u043du043eu0439 u043bu043eu0431u043du043eu0433u043e bones or the upper jaw until the u043fu0440u043eu043du0438u043au043du043eu0432u0435u043du0438u00a0 in the filled u0433u0438u0434u0440u043eu0433u0435u043b eat nasal cavity, then don't u043cu0435u043du00a0u00a0 parameters of laser u0438u0437u043bu0443u0447u0435u043du0438u00a0,to form the final u0434u0430u043au0440u0438u043eu0441u0442u043eu043cu0443 diameter of 2 - 5 mm in u0432u0440u0435u043cu00a0 reverse u0434u0432u0438u0436u0435u043du0438u00a0 fibre optics laser u0438u0437u043bu0443u0447u0435u043du0438u00a0 in position until the laser at u043eu043bu043eu043au043du0430 of u0434u0430u043au0440u0438u043eu0441u0442u043eu043cu044b, with u0432u0440u0435u043cu00a0 u0444u043eu0440u043cu0438u0440u043eu0432u0430u043du0438u00a0 u0434u0430u043au0440u0438u043eu0441u0442u043eu043cu044b laser radiation u0441u043eu0441u0442u0430u0432u043bu00a0u0435u0442 6 - 120 cthen, advancing the cannula with a laser u0441u0432u0435u0442u043eu0432u043eu0434u043eu043c in established u0434u0430u043au0440u0438u043eu0441u0442u043eu043cu0443 prior to the release of an in filled u0433u0438u0434u0440u043eu0433u0435u043bu0435u043c nasal cavity and not u0438u0437u043cu0435u043du00a0u00a0 polo by tip growth, u0443u0434u0430u043bu00a0u044eu0442 from growth light guide laser u0438u0437u043bu0443u0447u0435u043du0438u00a0 and u0432u0432u043eu0434u00a0u0442 in advance through the stent, which formed in the filled u0434u0430u043au0440u0438u043eu0441u0442u043eu043cu0443 u0433u0438u0434u0440u043eu0433u0435u043bu0435u043c nasal cavity.then through the nose end of the stent prior to u0432u044bu0432u043eu0434u00a0u0442 nasal cavity and u0437u0430u043au0440u0435u043fu043bu00a0u044eu0442 on the skin outside the nose of the patient, after which the u0443u0434u0430u043bu00a0u044eu0442 sharp growth of u0441u0444u043eu0440u043cu0438u0440u043eu0432u0430u043du043d oh u0434u0430u043au0440u0438u043eu0441u0442u043eu043cu044b in u0441u043bu0435u0437u043du043eu0439 bones or u043bu043eu0431u043du043eu043c process of upper jawin u0441u043bu0435u0437u043du0443u044e point on the upper or lower and upper or lower tires canadian in the nasal cavity through the established u0434u0430u043au0440u0438u043eu0441u0442u043eu043cu0443 u0432u0432u043eu0434u00a0u0442 probe u0440u0438u0442u043bu0435u043du0433u0430 and his ol with u043eu0441u0432u0435u0442 under control u0432u0432u043eu0434u00a0u0442 u043fu043eu043bu0438u043fu0440u043eu043fu0438u043bu0435u043du043eu0432u044bu0439 conductor silicon tubes to u043fu043eu00a0u0432u043bu0435u043du0438u00a0 in nasal cavity, u0443u0434u0430u043bu00a0u044eu0442 probe u0440u0438u0442u043bu0435u043du0433u0430, u0441u043du0438u043cu0430u00a0 him about u0432u043eu0434u043du0438u043au0430, second end stent u0432u0442u00a0u0433u0438u0432u0430u044eu0442 in nasal cavity for the conductor.at the first end of the stent u0432u044bu0432u043eu0434u00a0u0442 fixation and fixed outside the nose of a patient.